June 1, 2020 News by Mary Chapman FDA Updates Rebif Label on Pregnancy and Breastfeeding for MS Patients TheĀ U.S. Food and Drug Administration (FDA) approved adding new safety data on pregnancy and breastfeeding to the U.S. label for Rebif (interferon beta-1a), a disease-modifying treatment for relapsing forms of multiple sclerosis (MS). The label update draws on findings from a large population-based study, together with…
October 17, 2019 News by Patricia Inacio, PhD Rituximab Linked to Greater Risk of Infections in MS Patients in Real-world Swedish Study Newer disease-modifying treatments for multiple sclerosis (MS) are effective but also known to carry a greater risk of infections in a patient group already more likely to be troubled by infections ā and this higher risk is particularly evident in treatment with rituximab, a DMT often used off-label in…
December 10, 2018 Columns by Ed Tobias MS News that Caught My Eye Last Week: Palliative Care, Lemtrada and Lung Bleeding, Stroke Risk, Rebif Report Use of Hospital Palliative Care by MS Patients in US Rose 30-fold Between 2005-14, Study Finds Palliative care emphasizes prevention and relief of a patient’s suffering. Its goal is to improve the quality of life of that patient and his or her family. It’s usually thought of…
December 4, 2018 News by Jose Marques Lopes, PhD RRMS Patients on Rebif Show High Treatment Adherence and Fewer Relapses in Real-World Study Patients with relapsing-remitting multiple sclerosis (RRMS) onĀ Rebif (interferon beta 1-a), using the RebiSmart autoinjector, have high treatment adherence, despite seasonal weather or temperature fluctuations, as well as fewer relapses over one year, a real-world study reports. The study, āSeasonal adherence to, and effectiveness of,…
July 20, 2018 News by Patricia Inacio, PhD Single Gene Variant May Identify MS Patients at Risk of Liver Damage Linked to Interferon-Beta Use, Study Says A genetic variant close to a gene called interferon regulatory factor 6Ā (IRF6) may help to predict those multiple sclerosis (MS) patients most at risk of liver injury while using interferon-beta therapies, a study reports. The study, āCommon variation nearĀ IRF6Ā is associated with IFN-Ī²-induced liver injury in multiple sclerosisā was published…
April 20, 2018 News by Jose Marques Lopes, PhD #AAN2018 – Ocrevus Data Support Sustained Efficacy, Ability to Aid Cognition in RMS Patients Treatment with Ocrevus (ocrelizumab) shows sustained efficacy and an ability to improve cognition in patients with relapsing multiple sclerosis (MS), according to data being presented byĀ Genentech, the drug’s developer. The company will detail these findings in a series of oral and poster sessions at the 2018 American Academy…
January 23, 2018 Columns by Ed Tobias Who Are You to Tell Me What MS Therapy I Need? I’m used to seeing insurance companies here in the United States make decisions about MS therapies, including refusing to pay for certain treatments unless other, less expensive ones are tried first. These, of course, are decisions that should be made between patients and their doctors, not by insurers.